Figure 2From: Comparable outcomes for β-lactam/β-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae 30-day mortality for patients treated with BLBLI or carbapenem as definitive monotherapy.Back to article page